Smith & Nephew’s (SN) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their overweight rating on shares of Smith & Nephew (LON:SN) in a report issued on Thursday morning, Marketbeat reports. They currently have a GBX 1,300 ($16.18) target price on the stock.

Several other brokerages also recently issued reports on SN. Royal Bank of Canada reiterated an outperform rating and set a GBX 1,500 ($18.67) price target on shares of Smith & Nephew in a report on Friday, April 5th. Barclays reiterated an equal weight rating and set a GBX 1,150 ($14.32) price target on shares of Smith & Nephew in a report on Friday, February 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of GBX 1,362.50 ($16.96).

Smith & Nephew Trading Down 0.5 %

LON SN opened at GBX 961.80 ($11.97) on Thursday. The company has a market cap of £8.41 billion, a price-to-earnings ratio of 4,007.50, a P/E/G ratio of 0.46 and a beta of 0.51. Smith & Nephew has a 52 week low of GBX 887 ($11.04) and a 52 week high of GBX 1,316.75 ($16.39). The business has a 50 day moving average price of GBX 1,045.67 and a 200-day moving average price of GBX 1,033.97. The company has a quick ratio of 0.84, a current ratio of 1.77 and a debt-to-equity ratio of 59.11.

Smith & Nephew Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Thursday, March 28th will be given a $0.23 dividend. The ex-dividend date is Thursday, March 28th. This represents a yield of 1.62%. This is a boost from Smith & Nephew’s previous dividend of $0.14. Smith & Nephew’s payout ratio is currently 12,500.00%.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.